Innovation in pharma, chemistry, and biotech has never been more complex. Developing a new therapy, diagnostic, or digital solution requires not just brilliant science but collaboration across startups, corporates, OEMs, research institutions, and investors. Yet in many regions, these stakeholders remain disconnected. Startups struggle to find their first customers, corporates duplicate research instead of partnering, and promising technologies get delayed or lost in silos.
This is where ecosystem mapping comes in. By systematically visualizing the players, assets, and connections within a given innovation cluster, companies and policymakers gain clarity on where to focus, whom to partner with, and how to accelerate value creation. Done right, ecosystem mapping is not just an analytical tool, it’s a shortcut to faster innovation.
Without structured mapping, ecosystems often fall into familiar traps:
According to a BCG study (2023), regions with structured innovation clusters grow 30–50% faster in startup formation and investment than regions without them. In life sciences, where capital and timelines are critical, these differences are game-changing.
Ecosystem mapping is the process of identifying and structuring:
The output can be a digital dashboard, a searchable registry, or a visual map. More than just a database, it becomes a strategic tool for making better decisions, faster.
In the Ruhr/Westphalia region of Germany, initiatives like Klic2Go are creating digital “katasters” (registries) of bioanalytics and bioprocess assets. By cataloguing infrastructure across universities, corporates, and startups, they have:
This approach is spreading: similar cluster mapping initiatives are now visible in Cambridge (UK), Basel (Switzerland), and Boston (US). Each has shown that structured transparency increases trust, reduces duplication, and accelerates deal-making.
For OEMs, pharma, and startups, ecosystem mapping is not just policy-level work. It has direct impact on business:
In a world where 70% of innovation pilots fail to scale (PwC, 2022), targeting the right partner in the right ecosystem increases the odds of success dramatically.
Ecosystem mapping is not a luxury — it’s a practical accelerator. By creating visibility across stakeholders and assets, it reduces duplication, lowers costs, and speeds up collaboration. In fast-moving industries like pharma and biotech, where each year of delay can mean billions lost in opportunity, having a “map” is no longer optional.
Ecosystems that invest in transparency today will be the ones delivering breakthroughs tomorrow.
Great success in delivering projects and partnerships.